Syngene International Ltd

Syngene International Employee Stock Options

Syngene International Limited allotted 7,29,727 equity shares worth ₹0.73 Crore to the Syngene Employee Welfare Trust under its 2023 Long Term Incentive Plan. This issuance increases the company's total paid-up share capital to ₹403.67 Crore. The allotment was made at an exercise price of ₹10 per share.

Value

₹0.73 Cr

Syngene International Management Change

Syngene International approved the appointment of Mr. Vijaya Chandru and Mr. Arun Chandavarkar as Independent Directors for three-year terms starting July 2026. Additionally, Ms. Vinita Bali was reappointed as a Non-Executive Director for one year. These leadership updates, subject to shareholder approval, aim to strengthen the board's strategic oversight and governance.

Execution

3 years for new directors; 1 year for reappointed director

Syngene International Results Update

Syngene International reported full-year FY26 revenue of ₹3,739 Crore, up 3% year-on-year. Q4 revenue grew 2% to ₹1,037 Crore. The company announced leadership changes, with Ms. Kiran Mazumdar-Shaw becoming Executive Chairperson and Mr. Siddharth Mittal appointed as CEO effective July 2026. A final dividend of ₹1.25 per share was recommended.

Value

₹3,739 Cr

Syngene International Q4 FY26 Results: Net Profit ₹147.9 Cr, Down 19.3% YoY

Syngene International Ltd reported revenue from operations of ₹1,036 Cr (+1.8% YoY) and net profit of ₹147.9 Cr (-19.3% YoY) for Q4 FY26.

Key figure

Net profit ₹147.9 Cr · -19.3% YoY

Syngene International Financial Results

Syngene International reported FY26 consolidated total income of ₹3,809.4 Crore with a net profit of ₹316.7 Crore. The Board recommended a final dividend of ₹1.25 per share. It also approved the appointment of M/s S. R. Batliboi & Associates LLP as statutory auditors for five years starting from the 33rd AGM.

Value

₹3,809 Cr

Syngene International Board Meeting Outcome

Syngene International Limited has scheduled a Board Meeting on April 29, 2026, to consider audited standalone and consolidated financial results for the year ended March 31, 2026. The board will also recommend a final dividend. Trading windows remain closed from April 1 until May 1, 2026.

Syngene International Board Meeting Outcome

Syngene International Ltd will hold a Board Meeting on April 29, 2026, to approve audited financial results for the quarter and year ending March 31, 2026. The board will also consider recommending a final dividend. Consequently, the trading window is closed from April 01 to May 01, 2026.

Syngene International Q3 FY26 Results: Net Profit ₹15 Cr, Down 88.5% YoY

Syngene International Ltd reported net profit of ₹15 Cr (-88.5% YoY) for Q3 FY26.

Key figure

Net profit ₹15 Cr · -88.5% YoY